Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM): 22 pipeline candidates · 4 upcoming catalysts · ~58 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
57.5 months
D/E 12.07 · 0% dilution
Lead: Approved
22 candidates
4 upcoming, next in ~622d
0 buys · 16 sells (180d)
A transparent, data-derived signal for Axsome Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.9B
Cash
$305.1M
Quarterly Burn
$20.7M
Runway
57.5 mo
Revenue
$191.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (22 candidates)
| Drug | Phase |
|---|---|
| Auvelity | Approved |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
| av-001 | Phase 2 |
Showing 10 of 22 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
412
Total value held
$6.54B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,912,844 | $661.3M |
| vanguard capital management llc | 3,875,504 | $655.0M |
| vanguard portfolio management llc | 2,058,170 | $347.9M |
| fmr llc | 1,566,995 | $264.9M |
| geode capital management, llc | 1,162,981 | $196.6M |
| wellington management group llp | 1,145,306 | $193.6M |
| deep track capital, lp | 1,100,000 | $185.9M |
| state street corp | 986,809 | $166.8M |
| assenagon asset management s.a. | 865,958 | $146.4M |
| nomura asset management international inc. | 812,809 | $137.4M |
Showing top 10 of 412 institutional holders of Axsome Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Axsome Therapeutics, Inc.'s pipeline?
Axsome Therapeutics, Inc. (AXSM) has 22 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Axsome Therapeutics, Inc.'s lead drug candidate?
Axsome Therapeutics, Inc.'s most advanced tracked candidate is Auvelity (Approved) for major depressive disorder (MDD) in adults.
What is Axsome Therapeutics, Inc.'s next catalyst?
Axsome Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of" — expected March 1, 2028.
What is Axsome Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Axsome Therapeutics, Inc. has approximately 57.5 months of cash runway.
What is Axsome Therapeutics, Inc.'s market capitalization?
Axsome Therapeutics, Inc.'s market capitalization is approximately $12.9B.
Get the full picture on Axsome Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.